MYX mayne pharma group limited

Ann: Annual Report to shareholders, page-41

  1. 1,467 Posts.
    lightbulb Created with Sketch. 289
    Hard to understand MC being as low as it when owned our US manufacturing Complex / Metrics valuation around Companies entire MC company's turnover and assets impressive unfortunately we were saddled with impairments mainly our Teva debacle this impacted big time on Company's bottom line 5 years of heavy Net loses . Mayne after sale not the same company as it was when we owned Metrics an established manufacturing complex with profitable contracts with US Pharma companies . We were way undervalued considering solid assets surely an outstanding takeover opportunity for some large Pharma . Until management can prove itself and get Mayne now a much smaller company into net profit and our major product Nexstellis showing satisfactory sales can hardly expect MC being any higher than it is . Would have expected way more short term dividend interest , might be anticipating a downgrade by market analysts and risk getting stuck .
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$4.92
Change
-0.110(2.19%)
Mkt cap ! $399.7M
Open High Low Value Volume
$5.03 $5.03 $4.86 $1.730M 352.1K

Buyers (Bids)

No. Vol. Price($)
1 100 $4.88
 

Sellers (Offers)

Price($) Vol. No.
$4.93 25000 1
View Market Depth
Last trade - 16.15pm 23/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.